gip glp 1 agonists New strategies for the treatment of obesity and metabolic dysfunctions Upcoming wave of hormone-based therapies

Clinically, pigmented macules are typically solitary, well circumscribed lesions that average 6 mm in size

Frequency and risk factors of gout flares in a large population-based cohort of incident gout

There's no single "right" amount of water to add

Knocking out this gene promotes ferroptosis and inhibits prostate cancer cell growth [56]

The Evolution of GLP-1 Drugs: From Diabetes Treatment to Weight Management The GLP 1 story began with exenatides approval on April 28, 2005 marking the first GLP 1 receptor agonist available for type 2 diabetes

[1] Dose-escalation studies, such as a 12-week trial on gradual titration, revealed that beginning at lower doses (e.g., 4 mg) and slowly increasing to therapeutic levels significantly reduced the incidence of nausea, vomiting, and diarrhoea